Stockreport

Wegovy Priority Approval Puts Novo Nordisk Valuation And Risks In Focus [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Novo Nordisk (NYSE:NVO) received FDA approval for a higher dose of its obesity drug Wegovy under the National Priority Voucher program. The approval came through a fa [Read more]